Immunovant (IMVT) News Today $23.86 +0.06 (+0.25%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Immunovant CFO Eva Renee Barnett sells $54,756 in stockJanuary 18 at 1:25 AM | msn.comImmunovant CEO Peter Salzmann sells $208,899 in stockJanuary 17 at 8:24 PM | msn.comImmunovant, Inc. (NASDAQ:IMVT) CFO Sells $54,761.34 in StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) CFO Eva Renee Barnett sold 2,298 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $23.83, for a total transaction of $54,761.34. Following the completion of the transaction, the chief financial officer now directly owns 324,766 shares in the company, valued at approximately $7,739,173.78. The trade was a 0.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.January 17 at 4:55 PM | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Insider Sells $56,786.89 in StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) insider William L. Macias sold 2,383 shares of Immunovant stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $23.83, for a total value of $56,786.89. Following the completion of the transaction, the insider now directly owns 359,408 shares of the company's stock, valued at approximately $8,564,692.64. This trade represents a 0.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.January 17 at 4:55 PM | marketbeat.comPeter Salzmann Sells 8,767 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) CEO Peter Salzmann sold 8,767 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $23.83, for a total transaction of $208,917.61. Following the completion of the sale, the chief executive officer now owns 964,225 shares in the company, valued at approximately $22,977,481.75. This trade represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.January 17 at 4:55 PM | marketbeat.comIMUX Stock Touches 52-Week Low at $0.97 Amid Market ChallengesJanuary 17 at 3:23 PM | msn.comImmunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside PotentialJanuary 17 at 11:37 AM | insidermonkey.comImmunovant price target lowered to $45 from $48 at BofAJanuary 16 at 10:50 AM | markets.businessinsider.comBank of America Cuts Immunovant (NASDAQ:IMVT) Price Target to $45.00Bank of America reduced their target price on Immunovant from $48.00 to $45.00 and set a "buy" rating on the stock in a research report on Wednesday.January 16 at 9:27 AM | marketbeat.comSciences Ltd. Roivant Purchases 16,845,010 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockJanuary 16 at 5:42 AM | insidertrades.comJPMorgan Chase & Co. Lowers Stock Position in Immunovant, Inc. (NASDAQ:IMVT)JPMorgan Chase & Co. trimmed its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 11.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 228,257 shares of the company's stock afterJanuary 16 at 3:12 AM | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives $47.22 Average PT from BrokeragesImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and ten have assigned a buyJanuary 16 at 2:18 AM | marketbeat.comInsider Buying: Immunovant, Inc. (NASDAQ:IMVT) Director Buys 16,845,010 Shares of StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) Director Sciences Ltd. Roivant bought 16,845,010 shares of the firm's stock in a transaction on Monday, January 13th. The shares were bought at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the purchase, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.January 15 at 7:34 PM | marketbeat.comBank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock PriceBank of America dropped their price target on shares of Immunovant from $48.00 to $45.00 and set a "buy" rating for the company in a research note on Wednesday.January 15 at 8:50 AM | marketbeat.comImmunovant Progresses in Autoimmune Therapy DevelopmentJanuary 14, 2025 | tipranks.comImmunovant to sell 22.5M shares at $25.00 in private placementJanuary 14, 2025 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Sets New 52-Week Low - Here's WhyImmunovant (NASDAQ:IMVT) Sets New 1-Year Low - Time to Sell?January 14, 2025 | marketbeat.comImmunovant Announces $450 Million Private PlacementJanuary 13, 2025 | stockhouse.comImmunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Moderate Buy" by AnalystsJanuary 13, 2025 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) have been given an average rating of "Moderate Buy" by the ten ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy ratinJanuary 13, 2025 | marketbeat.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $98,930.50 in StockJanuary 13, 2025 | americanbankingnews.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells $123,030.50 in StockJanuary 13, 2025 | americanbankingnews.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CFO Sells 4,105 Shares of StockJanuary 11, 2025 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) CFO Sells $98,930.50 in StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) CFO Eva Renee Barnett sold 4,105 shares of Immunovant stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $24.10, for a total transaction of $98,930.50. Following the completion of the transaction, the chief financial officer now directly owns 327,064 shares of the company's stock, valued at approximately $7,882,242.40. This trade represents a 1.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 10, 2025 | marketbeat.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 5,105 Shares of StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) CEO Peter Salzmann sold 5,105 shares of the firm's stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $24.10, for a total transaction of $123,030.50. Following the completion of the sale, the chief executive officer now owns 972,992 shares of the company's stock, valued at $23,449,107.20. The trade was a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.January 10, 2025 | marketbeat.comQ1 Earnings Estimate for Immunovant Issued By Zacks ResearchImmunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities research analysts at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for Immunovant in a note issued to investors on Tuesday, January 7th. Zacks Research analyst E. Bagri now forecasts that the company will post earJanuary 10, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Sets New 12-Month Low - Here's What HappenedImmunovant (NASDAQ:IMVT) Reaches New 52-Week Low - Here's What HappenedJanuary 8, 2025 | marketbeat.comImmunovant downgraded to Peer Perform from Outperform at Wolfe ResearchJanuary 4, 2025 | markets.businessinsider.comWolfe Research Downgrades Immunovant (IMVT)January 4, 2025 | msn.comImmunovant (NASDAQ:IMVT) Shares Gap Down - Should You Sell?Immunovant (NASDAQ:IMVT) Shares Gap Down - Time to Sell?January 3, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Stock Rating Lowered by Wolfe ResearchWolfe Research lowered Immunovant from an "outperform" rating to a "peer perform" rating in a research report on Friday.January 3, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Stock Price Up 4.1% - What's Next?Immunovant (NASDAQ:IMVT) Trading 4.1% Higher - What's Next?December 31, 2024 | marketbeat.comKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmDecember 30, 2024 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Sets New 12-Month Low - Should You Sell?Immunovant (NASDAQ:IMVT) Sets New 12-Month Low - Here's What HappenedDecember 27, 2024 | marketbeat.comImmunovant: Continued FcRn Targeting With IMVT-1402 Pivotal StudyDecember 27, 2024 | seekingalpha.comImmunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Principal Financial Group Inc.Principal Financial Group Inc. increased its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 69.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 951,124 shares of theDecember 25, 2024 | marketbeat.comGeode Capital Management LLC Buys 96,924 Shares of Immunovant, Inc. (NASDAQ:IMVT)Geode Capital Management LLC lifted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 6.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,510,926 shares of the company's sDecember 24, 2024 | marketbeat.comImmunovant price target lowered to $45 from $47 at Wells FargoDecember 20, 2024 | finance.yahoo.comWells Fargo & Company Lowers Immunovant (NASDAQ:IMVT) Price Target to $45.00Wells Fargo & Company lowered their price objective on shares of Immunovant from $47.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday.December 19, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Stock Holdings Lessened by Franklin Resources Inc.Franklin Resources Inc. lessened its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 4.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,049,679 shares of the company's stock after selling 52,189 shares during the period. Franklin ResourcDecember 19, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Recommendation of "Buy" from AnalystsImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) has earned an average rating of "Buy" from the ten ratings firms that are currently covering the company, Marketbeat.com reports. Ten analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have coDecember 19, 2024 | marketbeat.comImmunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's WhyImmunovant (NASDAQ:IMVT) Stock Price Down 5.2% - Here's What HappenedDecember 18, 2024 | marketbeat.comState Street Corp Acquires 303,386 Shares of Immunovant, Inc. (NASDAQ:IMVT)State Street Corp boosted its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 11.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,022,342 shares of the company's stock after buying an additional 303,386 shares during the periodDecember 17, 2024 | marketbeat.comFcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal TrialDecember 11, 2024 | globenewswire.comCharles Schwab Investment Management Inc. Increases Position in Immunovant, Inc. (NASDAQ:IMVT)Charles Schwab Investment Management Inc. lifted its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 19.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 552,430 shares of the company's stock after acquDecember 8, 2024 | marketbeat.comRedmile Group LLC Has $18.31 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT)Redmile Group LLC cut its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 10.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 642,229 shares of the company's stock after selling 7December 5, 2024 | marketbeat.comBamco Inc. NY Has $855,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT)Bamco Inc. NY cut its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 45.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,000 shares of the company's stock afteDecember 4, 2024 | marketbeat.com52,500 Shares in Immunovant, Inc. (NASDAQ:IMVT) Bought by Erste Asset Management GmbHErste Asset Management GmbH acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 52,500 shares of the company's stock, valued atDecember 4, 2024 | marketbeat.comBaker BROS. Advisors LP Buys 760,692 Shares of Immunovant, Inc. (NASDAQ:IMVT)Baker BROS. Advisors LP boosted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 163.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,225,410 shares of the company's stock after purchasing an adDecember 2, 2024 | marketbeat.comFmr LLC Acquires 2,053,688 Shares of Immunovant, Inc. (NASDAQ:IMVT)Fmr LLC boosted its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 19.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,537,571 shares of the company's stock after acquiring an additionalDecember 1, 2024 | marketbeat.com Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Media Mentions By Week IMVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMVT News Sentiment▼0.220.68▲Average Medical News Sentiment IMVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMVT Articles This Week▼305▲IMVT Articles Average Week Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News Today MRNA News Today RDY News Today CTLT News Today SRPT News Today QGEN News Today PCVX News Today ASND News Today ROIV News Today RVMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMVT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
